Skip to main content

Table 1 Baseline demographic characteristics for patients with or without cancer (safety population)

From: Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

  Pts with cancer at admission Pts without cancer at admission
  Certoparin
(n = 133)
UFH
(n = 141)
Total
(n = 274)
Total
(n = 2965)
p-value vs. pts with cancer
Female (%) 37.6 40.4 39.1 61.0 < 0.0001^
Mean age (± SD) (y) 79.7 ± 6.4 78.3 ± 5.8 79.0 ± 6.1 78.8 ± 6.3 0.6922~
Mean bodyweight (± SD) (kg) 73.4 ± 14.6 71.2 ± 13.7 72.3 ± 14.2 72.1 ± 15.9 0.8076~
Body Mass Index (± SD) (kg/m2) 25.9 ± 4.5 25.4 ± 4.6 25.6 ± 4.6 26.6 ± 5.4 0.0041~
Reason for hospitalization (%)      
   Infections and infestations 23.3 28.4 25.9 27.7 0.5210^
   Cardiac disorders 14.3 8.5 11.3 23.2 < 0.0001^
   Respiratory disease 6.8 10.6 8.8 18.0 < 0.0001^
   Neurologic disease 6.8 6.4 6.6 6.6 0.9791^
   Gastrointestinal disease 9.0 9.2 9.1 6.3 0.0753^
   Vascular disease 3.0 6.4 4.7 5.9 0.4454^
Renal status      
   GFR ≤ 30 ml/min/1.73 m2 4.6 2.9 3.7 6.1 0.1106*
   30 < GFR ≤ 60 ml/min/1.73 m2 52.7 50.0 51.3 52.2  
   GFR > 60 ml/min/1.73 m2 42.7 47.1 45.0 41.6  
Antiplatelet use      
   Yes 51.1 48.9 50.0 52.2 0.4905^
   No 48.9 51.1 50.0 47.8  
Hospitalization (mean ± SD) (days) 13.0 ± 8.5 12.6 ± 5.2 12.8 ± 7.0 12.3 ± 6.0 0.2500~
Immobilization (mean ± SD) (days) 10.7 ± 6.3 10.7 ± 4.5 10.7 ± 5.5 9.8 ± 4.2 0.0038~
Mean exposure (± SD) (days) 9.2 ± 3.9 9.1 ± 4.0 9.2 ± 3.9 9.1 ± 3.3 0.6264~
  1. Legend: Pts, patients; SD, standard deviation; UFH, unfractionated heparin; ^ Chi-Square Test; * Chi-Square Test comparing only GFR ≤ 30 ml/min/1.73 m2; ~ t-Test.